CTLA-4 blockade-based anti-tumor immunity was augmented upon prior vaccination with autologous and irradiated tumor cells engineered to secrete GM-CSF, in patients suffering from metastatic melanoma or ovarian carcinoma (Hodi et al, 2008). The gene discussed is CTLA4; the disease is metastatic melanoma.